Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression

Human Molecular Genetics

Volumn 24, Issue 21, 2015, Pages 6013-6028

  Henry, Anastasia G ^a   Aghamohammadzadeh, Soheil ^a,b   Samaroo, Harry ^a   Chen, Yi ^a   Mou, Kewa ^a   Needle, Elie ^a,c   Hirst, Warren D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Proteostasis Therapeutics   (United States)

^c Vaccine Research East and Early Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ATP13A2 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PF 06447475; PHOSPHOTRANSFERASE INHIBITOR; SERINE; UNCLASSIFIED DRUG; ATP13A2 PROTEIN, MOUSE; LRRK2 PROTEIN, MOUSE; MEMBRANE PROTEIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ATP13A2 GENE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LRRK2 GENE; LYSOSOME; MORPHOLOGY; MOUSE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PH; PHOSPHORYLATION; TRANSGENIC MOUSE; UPREGULATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ASTROCYTES; BRAIN; CELLS, CULTURED; HUMANS; HYDROGEN-ION CONCENTRATION; LYSOSOMES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PARKINSON DISEASE; PHENOTYPE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84942441789     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv314     Document Type: Article

References (85)

1. He, C., Klionsky, D.J. (2009) Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet., 43, 67-93.
2. Luzio, J.P., Pryor, P.R., Bright, N.A. (2007) Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol., 8, 622-632.
3. Mellman, I. (1996) Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol., 12, 575-625.
4. Scott, C.C., Vacca, F., Gruenberg, J. (2014) Endosome maturation, transport and functions. Semin. Cell Dev. Biol., 31, 2-10.
5. Kroemer, G., Jaattela, M. (2005) Lysosomes and autophagy in cell death control. Nat. Rev. Cancer, 5, 886-897.
6. Saftig, P., Klumperman, J. (2009) Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol., 10, 623-635.
7. Settembre, C., Fraldi, A., Medina, D.L., Ballabio, A. (2013) Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol., 14, 283-296.
8. Dehay, B., Martinez-Vicente, M., Caldwell, G.A., Caldwell, K. A., Yue, Z., Cookson, M.R., Klein, C., Vila, M., Bezard, E. (2013) Lysosomal impairment in Parkinson's disease. Mov. Disord., 28, 725-732.
9. Maxfield, F.R. (2014) Role of endosomes and lysosomes in human disease. Cold Spring Harb. Perspect Biol., 6, a016931.
10. Platt, F.M., Boland, B., van der Spoel, A.C. (2012) Lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol., 199, 723-734.
11. Dickson, D.W. (2012) Parkinson's disease and Parkinsonism: neuropathology. Cold Spring Harb. Perspect Med., 2, 1-15.
12. Spillantini, M.G., Schmidt, M.L., Lee, V.M.Y., Trojanowski, J.Q., Jakes, R., Goedert, M. (1997) [alpha]-Synuclein in Lewy bodies. Nature, 388, 839-840.
13. Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M.T., Michel, P.P., Marquez, J., Mouatt-Prigent, A., Ruberg, M., Hirsch, E.C., Agid, Y. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol., 12, 25-31.
14. Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., Vila, M. (2010) Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci., 30, 12535-12544.
15. Chu, Y., Dodiya, H., Aebischer, P., Olanow, C.W., Kordower, J.H. (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alphasynuclein inclusions. Neurobiol. Dis., 35, 385-398.
16. Alvarez-Erviti, L., Rodriguez-Oroz, M.C., Cooper, J.M., Caballero, C., Ferrer, I., Obeso, J.A., Schapira, A.H.V. (2010) Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol., 67, 1464-1472.
17. Manzoni, C., Lewis, P.A. (2013) Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J., 27, 3424-3429.
18. Latourelle, J.C., Sun, M., Lew, M.F., Suchowersky, O., Klein, C., Golbe, L.I., Mark, M.H., Growdon, J.H., Wooten, G.F., Watts, R.L., et al. (2008) The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med., 6, 32-32.
19. Mills, R.D., Mulhern, T.D., Cheng, H.C., Culvenor, J.G. (2012) Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. Biochem. Soc. Trans., 40, 1086-1089.
20. Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci., 11, 791-797.
21. Nichols, W.C., Pankratz, N., Hernandez, D., Paisan-Ruiz, C., Jain, S., Halter, C.A., Michaels, V.E., Reed, T., Rudolph, A., Shults, C.W., et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet, 365, 410-412.
22. Gilks, W.P., Abou-Sleiman, P.M., Gandhi, S., Jain, S., Singleton, A., Lees, A.J., Shaw, K., Bhatia, K.P., Bonifati, V., Quinn, N.P., et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, 365, 415-416.
23. Di Fonzo, A., Rohe, C.F., Ferreira, J., Chien, H.F., Vacca, L., Stocchi, F., Guedes, L., Fabrizio, E., Manfredi, M., Vanacore, N., et al. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet, 365, 412-415.
24. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M.P., Nomanbhoy, T.K., Alessi, D.R., et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol., 7, 203-205.
25. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M., Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
26. Shin, N., Jeong, H., Kwon, J., Heo, H.Y., Kwon, J.J., Yun, H.J., Kim, C.-H., Han, B.S., Tong, Y., Shen, J., et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res., 314, 2055-2065.
27. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.-W., Savitt, J.M., Waldvogel, H.J., et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 60, 557-569.
28. Orenstein, S.J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L.S., Dauer, W., Consiglio, A., et al. (2013) Interplay of LRRK2 with chaperonemediated autophagy. Nat. Neurosci., 16, 394-406.
29. MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, BrianD., Marder, KarenS., Honig, LawrenceS., Clark, LorraineN., Small, ScottA., et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron, 77, 425-439.
30. Hockey, L.N., Kilpatrick, B.S., Eden, E.R., Lin-Moshier, Y., Brailoiu, G.C., Brailoiu, E., Futter, C.E., Schapira, A.H., Marchant, J.S., Patel, S. (2015) Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. J. Cell Sci., 128, 232-238.
31. Beilina, A., Rudenko, I.N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S.K., Kalia, L.V., Lobbestael, E., Chia, R., Ndukwe, K., et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl. Acad. Sci. USA, 111, 2626-2631.
32. Manzoni, C., Mamais, A., Dihanich, S., Abeti, R., Soutar, M.P., Plun-Favreau, H., Giunti, P., Tooze, S.A., Bandopadhyay, R., Lewis, P.A. (2013) Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim. Biophys. Acta., 1833, 2900-2910.
33. Piccoli, G., Condliffe, S.B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., Meixner, A., Sarioglu, H., Vogt-Weisenhorn, D.M., Wurst, W., et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci., 31, 2225-2237.
34. Dodson, M.W., Zhang, T., Jiang, C., Chen, S., Guo, M. (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum. Mol. Genet., 21, 1350-1363.
35. Zhang, Y., Chen, K., Sloan, S.A., Bennett, M.L., Scholze, A.R., O'Keeffe, S., Phatnani, H.P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci., 34, 11929-11947.
36. Tong, Y., Giaime, E., Yamaguchi, H., Ichimura, T., Liu, Y., Si, H., Cai, H., Bonventre, J.V., Shen, J. (2012) Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol. Neurodeg., 7, 2.
37. Bravo-San Pedro, J., Niso-Santano, M., Gómez-Sánchez, R., Pizarro-Estrella, E., Aiastui-Pujana, A., Gorostidi, A., Climent, V., López de Maturana, R., Sanchez-Pernaute, R., López de Munain, A., et al. (2013) The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell. Mol. Life Sci., 70, 121-136.
38. Sánchez-Danés, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jiménez-Delgado, S., Caig, C., Mora, S., Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., et al. (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med., 4, 380-395.
39. Gómez-Suaga, P., Luzón-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P.G., Churchill, G.C., Hilfiker, S. (2012) Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet., 21, 511-525.
40. Alegre-Abarrategui, J., Christian, H., Lufino, M.M.P., Mutihac, R., Venda, L.L., Ansorge, O., Wade-Martins, R. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet., 18, 4022-4034.
41. Plowey, E.D., Cherra, S.J., Liu, Y.-J., Chu, C.T. (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem., 105, 1048-1056.
42. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R.J. 3rd and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U S A, 107, 9879-9884.
43. Coffey, E.E., Beckel, J.M., Laties, A.M., Mitchell, C.H. (2014) Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience, 263, 111-124.
44. Golabek, A.A., Kida, E., Walus, M., Kaczmarski, W., Michalewski, M., Wisniewski, K.E. (2000) CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-ß protein precursor and cathepsin D in human cells. Mol. Genet. Met., 70, 203-213.
45. Lee, J.-H., Yu, W.H., Kumar, A., Lee, S., Mohan, P.S., Peterhoff, C.M., Wolfe, D.M., Martinez-Vicente, M., Massey, A.C., Sovak, G., et al. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell, 141, 1146-1158.
46. Dzamko, N., Deak, M., Hentati, F., Reith, A.D., Prescott, A.R., Alessi, D.R., Nichols, R.J. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J., 430, 405-413.
47. Higashi, S., Moore, D.J., Yamamoto, R., Minegishi, M., Sato, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., Hino, H., et al. (2009) Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J. Neuropath. Exp. Neurol., 68, 994-1005.
48. Hatano, T., Kubo, S.-i., Imai, S., Maeda, M., Ishikawa, K., Mizuno, Y., Hattori, N. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet., 16, 678-690.
49. Henderson, J.L., Kormos, B.L., Hayward, M.M., Coffman, K.J., Jasti, J., Kurumbail, R.G., Wager, T.T., Verhoest, P.R., Noell, G.S., Chen, Y., et al. (2014) Discovery and preclinical profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl] benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J. Med. Chem., 58, 419-432.
50. Reynolds, A., Doggett, E.A., Riddle, S.M., Lebakken, C.S., Nichols, R.J. (2014) LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front. Mol. Neurosci., 7, 54.
51. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C.E., Dominguez, S.L., Solanoy, H.O., Drummond, J., Zhang, X., Ding, X., et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med., 4, 164ra161.
52. Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.-H., Doudnikoff, E., Vital, A., Vila, M., Klein, C., Bezard, E. (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. Acad. Sci. USA, 109, 9611-9616.
53. Ramonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., Pletnikova, O., Troncoso, J.C., Glauser, L., Moore, D.J. (2012) PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet., 21, 1725-1743.
54. Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L.P., Goebel, I., Mubaidin, A.F., Wriekat, A.-L., Roeper, J., et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet., 38, 1184-1191.
55. Murphy, K.E., Cottle, L., Gysbers, A.M., Cooper, A.A., Halliday, G.M. (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta. Neuropath. Comm., 1, 11.
56. Giesert, F., Hofmann, A., Burger, A., Zerle, J., Kloos, K., Hafen, U., Ernst, L., Zhang, J., Vogt-Weisenhorn, D.M., Wurst, W. (2013) Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS One, 8, e63778.
57. Miklossy, J., Arai, T., Guo, J.P., Klegeris, A., Yu, S., McGeer, E.G., McGeer, P.L. (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol., 65, 953-963.
58. Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M., West, A.B. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci., 32, 1602-1611.
59. Maragakis, N.J., Rothstein, J.D. (2006) Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol., 2, 679-689.
60. Allaman, I., Belanger, M., Magistretti, P.J. (2011) Astrocyteneuron metabolic relationships: for better and for worse. Trends Neurosci., 34, 76-87.
61. Gu, X.L., Long, C.X., Sun, L., Xie, C., Lin, X., Cai, H. (2010) Astrocytic expression of Parkinson's disease-related A53 T alpha-synuclein causes neurodegeneration in mice. Mol. Brain, 3, 12.
62. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587-593.
63. Guerreiro, P., Gerhardt, E., Lopes da Fonseca, T., Bähr, M., Outeiro, T., Eckermann, K. (2015) LRRK2 promotes Tau accumulation, aggregation and release. Mol. Neurobiol., 52, 1-12.
64. Lichtenberg, M., Mansilla, A., Zecchini, V.R., Fleming, A., Rubinsztein, D.C. (2011) The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell. Death Dis., 2, e196.
65. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.-L., Dawson, V.L., et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 16, 223-232.
66. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA, 102, 16842-16847.
67. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A., Cookson, M.R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Comm., 357, 668-671.
68. Guo, L., Gandhi, P.N., Wang, W., Petersen, R.B., Wilson-Delfosse, A.L., Chen, S.G. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Exp. Cell Res., 313, 3658-3670.
69. Daniëls, V., Vancraenenbroeck, R., Law, B.M.H., Greggio, E., Lobbestael, E., Gao, F., De Maeyer, M., Cookson, M.R., Harvey, K., Baekelandt, V., et al. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem., 116, 304-315.
70. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A., Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of howParkinson's disease mutants affect kinase activity. Biochem. J., 405, 307-317.
71. Gandhi, P.N., Wang, X., Zhu, X., Chen, S.G., Wilson-Delfosse, A.L. (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res., 86, 1711-1720.
72. Gómez-Suaga, P., Rivero-Ríos, P., Fdez, E., Blanca Ramírez, M., Ferrer, I., Aiastui, A., López De Munain, A., Hilfiker, S. (2014) LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum. Mol. Genet., 23, 6779-6796.
73. Kett, L.R., Boassa, D., Ho, C.C.-Y., Rideout, H.J., Hu, J., Terada, M., Ellisman, M., Dauer, W.T. (2012) LRRK2 Parkinson disease mutations enhance its microtubule association. Hum. Mol. Genet., 21, 890-899.
74. Meixner, A., Boldt, K., Van Troys, M., Askenazi, M., Gloeckner, C.J., Bauer, M., Marto, J.A., Ampe, C., Kinkl, N., Ueffing, M. (2011) A QUICK screen for Lrrk2 interaction partners- leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell. Proteo., 10, 1-17.
75. Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.-L., Long, C.-X., Lobbestael, E., Baekelandt, V., Taymans, J.-M., Sun, L., et al. (2009) Phosphorylation of Ezrin/Radixin/Moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci., 29, 13971-13980.
76. Matsui, H., Sato, F., Sato, S., Koike, M., Taruno, Y., Saiki, S., Funayama, M., Ito, H., Taniguchi, Y., Uemura, N., et al. (2013) ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons. FEBS Letters, 587, 1316-1325.
77. Usenovic, M., Tresse, E., Mazzulli, J.R., Taylor, J.P., Krainc, D. (2012) Deficiency of ATP13A2 leads to lysosomal dysfunction, a-synuclein accumulation, and neurotoxicity. J. Neurosci., 32, 4240-4246.
78. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., Björklund, A. (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from a-synuclein toxicity. Proc. Natl. Acad. Sci. USA, 110, E1817-E1826.
79. Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., Rice, M.E., Yue, Z. (2010) Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S. J. Neurosci., 30, 1788-1797.
80. Hinkle, K.M., Yue, M., Behrouz, B., Dachsel, J.C., Lincoln, S.J., Bowles, E.E., Beevers, J.E., Dugger, B., Winner, B., Prots, I., et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegen., 7, 25.
81. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S., et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet., 20, 4209-4223.
82. Liu, J., Lu, W., Reigada, D., Nguyen, J., Laties, A.M., Mitchell, C.H. (2008) Restoration of lysosomal pH in RPE cells from cultured human and ABCA4-/-mice: pharmacologic approaches and functional recovery. Invest. Ophthal. Vis. Sci., 49, 772-780.
83. Li, K., Yang, L., Zhang, C., Niu, Y., Li, W., Liu, J.-J. (2014) HPS6 interacts with dynactin p150Glued to mediate retrograde trafficking and maturation of lysosomes. J. Cell Sci., 127, 4574-4588.
84. Creasy, B.M., Hartmann, C.B., White, F.K.H., McCoy, K.L. (2007) New assay using fluorogenic substrates and immunofluorescence staining to measure cysteine cathepsin activity in live cell subpopulations. Cytometry Part A, 71A, 114-123.
85. Roberts, E., Deretic, V. (2008) Autophagic proteolysis of long-lived proteins in nonliver cells. Methods Mol. Biol., 445, 111-117.